H19 and carcinoma: Functional assays in both ER(+)-MCF-7 and ER(-)-Triple negative breast cancer (TNBC) carcinomas have shown that acquisition of resistance to PTX requires the upregulation of H19 (Figure 1B), which in turn blocks activation of several apoptotic pathways.